- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
19 result(s) found for: neurofibromatosis type 1.
Displaying page 1 of 1.
EudraCT Number: 2011-001789-16 | Sponsor Protocol Number: PenCTU/2011/CTIMP-005 | Start Date*: 2011-08-26 | |||||||||||
Sponsor Name:Plymouth Hospital NHS Trust | |||||||||||||
Full Title: Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas | |||||||||||||
Medical condition: Neurofibromatosis, type 2 (acoustic neurofibromatosis) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003405-26 | Sponsor Protocol Number: NF1-EXCEL | Start Date*: 2014-09-03 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) | |||||||||||||
Medical condition: Neurofibromatosis type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) BE (Ongoing) DK (Prematurely Ended) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005770-26 | Sponsor Protocol Number: KRONF2 | Start Date*: 2023-10-20 | ||||||||||||||||
Sponsor Name:Medical University of Warsaw | ||||||||||||||||||
Full Title: Phase 2a non-commercial and non-randomized intervention study evaluating the efficacy of crizotinib in the treatment of children with severe type 2 neurofibromatosis, in particular those excluded f... | ||||||||||||||||||
Medical condition: Neurofibromatosis type 2 is a genetically determined primary malignancy resulting from a mutation that disables the function of the cell division control gene and leads to neoplasia such as benign ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005607-39 | Sponsor Protocol Number: D134BC00001 | Start Date*: 2021-10-05 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Multicentre, International Study with a Parallel, Randomised, Double blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with... | |||||||||||||
Medical condition: Neurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Restarted) PL (Trial now transitioned) IT (Ongoing) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005742-38 | Sponsor Protocol Number: SANTA2012 | Start Date*: 2013-05-02 | |||||||||||
Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Early phase triple blind placebo controlled RCT of simvastatin treatment for autism in young children with Neurofibromatosis Type 1 | |||||||||||||
Medical condition: Neurofibromatosis Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005648-52 | Sponsor Protocol Number: D1346C00015 | Start Date*: 2021-05-31 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase I, Single-Arm, Sequential Study to Evaluate the Effect of Food on the Gastrointestinal Tolerability and Pharmacokinetics of Selumetinib after Multiple Doses in Adolescent Children with Neur... | |||||||||||||
Medical condition: Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005608-20 | Sponsor Protocol Number: D1346C00004 | Start Date*: 2021-11-24 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase I/II, Single-Arm, Open label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥ 1 to < 7 Years with Neurofibr... | |||||||||||||
Medical condition: Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) NL (Prematurely Ended) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005022-10 | Sponsor Protocol Number: SYN-1748-MAL-0030-I | Start Date*: 2018-02-13 | ||||||||||||||||
Sponsor Name:Technische Universität München, Fakultät für Medizin | ||||||||||||||||||
Full Title: Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | ||||||||||||||||||
Medical condition: Noonan Syndrom and Neurofibromatosis Type 1 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-001572-42 | Sponsor Protocol Number: FCN-159-002 | Start Date*: 2021-12-21 | |||||||||||
Sponsor Name:Shanghai Fosun Pharmaceutical Industrial Development Co.,Ltd. | |||||||||||||
Full Title: A multi-center, open-label, single-arm Phase I dose-escalation and Phase II dose-expansion study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of FCN-159 in adult... | |||||||||||||
Medical condition: Participants diagnosed with Neurofibromatosis NF1-related plexiform neurofibromas (PN) and symptomatic with requirement of systematic therapy per investigator’s judgment. A PN is defined as a neuro... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Ongoing) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001563-36 | Sponsor Protocol Number: CRAD001MIL04T | Start Date*: 2016-05-12 |
Sponsor Name:Novartis Pharmaceuticals | ||
Full Title: A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1) | ||
Medical condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 | ||
Disease: | ||
Population Age: Children, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-001846-32 | Sponsor Protocol Number: BUS2018-1 | Start Date*: 2018-09-18 |
Sponsor Name:VO Barnmedicin, Skånes University Hospital | ||
Full Title: Treatment of NF1-related plexiform neurofibroma with trametinib; a single arm, open-label trial with the goals of volumetric partial remission and pain relief | ||
Medical condition: NF1-related plexiform neurofibroma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000156-35 | Sponsor Protocol Number: NF2PET | Start Date*: 2021-03-18 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: 89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2. | ||
Medical condition: Neurofibromatosis type 2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016922-15 | Sponsor Protocol Number: HSJD-IMANF1 | Start Date*: 2010-02-04 |
Sponsor Name:HOSPITAL SANT JOAN DE DÉU | ||
Full Title: ENSAYO PILOTO CON IMATINIB PARA PACIENTES CON NEUROFIBROMA PLEXIFORME ASOCIADO A LA NEUROFIBROMATOSIS TIPO I. PILOT STUDY WITH IMATINIB FOR PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE I PATIENTS | ||
Medical condition: Tratamiento de los neurofibromas plexiformes de alto riesgo no abordables quirúrgicamente en pacientes con neurofibromatosis tipo I | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001317-16 | Sponsor Protocol Number: TRAIN_2019 | Start Date*: 2019-10-30 | ||||||||||||||||
Sponsor Name:ErasmusMC | ||||||||||||||||||
Full Title: The TRAIN study: TRAmetinib In Neurofibromatosis type 1 related symptomatic plexiform neurofibromas | ||||||||||||||||||
Medical condition: Adult patients (age >17 years) with (mosaic) NF1 with inoperable symptomatic plexiform neurofibromas | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002635-41 | Sponsor Protocol Number: 15HI53 | Start Date*: 2018-09-26 | |||||||||||||||||||||
Sponsor Name:Great Ormond Street Hospital | |||||||||||||||||||||||
Full Title: A paediatric phase I/II study of intermittent dosing of the MEK-1 inhibitor selumetinib in children with neurofibromatosis type-1 and inoperable plexiform neurofibroma and/or progressive optic path... | |||||||||||||||||||||||
Medical condition: Neurofibromatosis type 1 associated plexiform neurofibromas Neurofibromatosis type 1 associated progressive or relapsed optic pathway glioma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000847-16 | Sponsor Protocol Number: D1532C00057 | Start Date*: 2019-01-29 | |||||||||||
Sponsor Name:National Cancer Institute, Cancer Therapy Evaluation Program | |||||||||||||
Full Title: A Phase 1/2 Study of the Mitogen Activated Protein Kinase Kinase(MEK) 1 Inhibitor Selumetinib (AZD6244, ARRY-142886, Hydrogen Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable... | |||||||||||||
Medical condition: Neurofibromatosis type 1 (NF1) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005377-29 | Sponsor Protocol Number: CNS 2004 03 | Start Date*: 2006-05-03 |
Sponsor Name:Dept of Pediatrics, University Hospital of North Norway | ||
Full Title: SIOP-LGG 2004 Cooperative multicenter Study for Children and Adolescents with Low Grade Gliome | ||
Medical condition: Low Grade Glioma | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Ongoing) IE (Completed) GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001982-26 | Sponsor Protocol Number: OZM-063 | Start Date*: 2018-04-26 | |||||||||||
Sponsor Name:The Hospital for Sick Children | |||||||||||||
Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma... | |||||||||||||
Medical condition: Unresectable or progressive low grade glioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003005-10 | Sponsor Protocol Number: IGR2012/1883 | Start Date*: 2013-06-06 | |||||||||||||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||||||||||||
Full Title: PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA | |||||||||||||||||||||||
Medical condition: Children, adolescents and young adults with refractory or recurrent low-grade gliomas, and children, adolescents and young adults with neurofibromatosis type 1 and previously untreated low-grade g... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) FR (Ongoing) NL (Completed) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.